Ohhh Errol
Norm Smith Medallist
Pfizer getting ahead of the next curve buying blood cancer company Trillium.
Pfizer to buy cancer drug developer Trillium in $3.1b deal
Trillium’s two lead molecules, TTI-622 and TTI-621, block signalling proteins involved in blood cancers, and are both in human trials across several types of disease.
www.smh.com.au